Skip to main
NUVL
NUVL logo

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc is positioned favorably in the biopharmaceutical market, particularly due to its innovative product candidates, NVL-520 and NVL-655, which have shown deep and durable antitumor responses with improved tolerability, thereby enhancing their potential to transform treatment paradigms within the oncology space. The company is targeting a significant expansion of the oncogene-driven non-small cell lung cancer (NSCLC) market, with a projected peak revenue opportunity exceeding $3.6 billion, particularly as newer detection methods for ROS1 fusions gain traction in clinical practice. Additionally, the promising preclinical data for NVL-330, combined with positive developments from ongoing studies, suggests a robust pipeline that could lead to higher risk-adjusted sales estimates, enhancing the overall financial outlook for Nuvalent.

Bears say

Nuvalent's stock outlook is negatively impacted by concerns regarding its clinical candidates, particularly their safety profiles and efficacy, which may hinder regulatory approval and competitive positioning in the oncology market. The potential for adverse trial outcomes, delays in research and development, and a competitive landscape filled with established treatments further exacerbates the challenges faced by the company. Additionally, the risk of not securing adequate capital for ongoing research initiatives could significantly limit Nuvalent's operational capabilities and growth prospects.

Nuvalent (NUVL) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 14 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.